We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+39.41%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$82.4M
AUM Growth
-$160M
Cap. Flow
-$197M
Cap. Flow %
-238.52%
Top 10 Hldgs %
72.4%
Holding
35
New
12
Increased
–
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$5.56M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$2.73M
3
AMRN
Amarin Corp
AMRN
+$2.68M
4
ACOR
Acorda Therapeutics
ACOR
+$2.32M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.01M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$24.3M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$14.7M
3
INSM icon
Insmed
INSM
+$14.4M
4
HRTX icon
Heron Therapeutics
HRTX
+$11.3M
5
BHC icon
Bausch Health
BHC
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
26
Gyre Therapeutics
GYRE
$648M
– –
-50,135
Closed -$2.97M
MDWD icon
27
MediWound
MDWD
$181M
– –
-14,935
Closed -$424K
STRO icon
28
Sutro Biopharma
STRO
$411M
– –
-24,950
Closed -$2.25M
TEVA icon
29
CALL
Teva Pharmaceuticals
TEVA
$41.2B
– –
-1,683,500
Closed -$26M
XBI icon
30
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-499,200
Closed -$35.8M
VCNX
31
DELISTED
Vaccinex, Inc. Common Stock
VCNX
– –
-81
Closed -$62K
RVLP
32
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-120,620
Closed -$935K
ATNX
33
DELISTED
Athenex, Inc. Common Stock
ATNX
– –
-6,165
Closed -$1.56M
ZSAN
34
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-22,821
Closed -$1.69M
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-396,198
Closed -$7.74M
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Nexthera Capital held 35 positions worth $82.4M, down 66% from $243M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Nexthera Capital withdrew a net $197M in Q1 2019, closing 11 positions and reducing 12 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $7.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 57% a quarter earlier.

Against the trend, Nexthera Capital opened a new position in UroGen Pharma worth $4.9M.

  • Nexthera Capital's largest Q1 2019 buy was UroGen Pharma: 132,589 shares worth $4.9M.
  • Nexthera Capital's biggest Q1 2019 reduction was Novartis, cutting an estimated $24.3M.
  • Nexthera Capital fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019, selling an estimated $7.74M.
  • Nexthera Capital's ten largest holdings make up 72% of its $82.4M portfolio in Q1 2019.
  • Nexthera Capital opened 12 new positions and closed 11 in Q1 2019.
  • Nexthera Capital's portfolio value fell 66% quarter-over-quarter to $82.4M.

Based on Nexthera Capital's 13F filing for Q1 2019, filed 15 May 2019.